Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung

BACKGROUND: Alectinib is a highly selective tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK) and provided a significantly prolonged progression-free survival compared with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) harboring rearrangements of the ALK gene....

Descripción completa

Detalles Bibliográficos
Autores principales: Imanishi, Naoko, Yoneda, Kazue, Taira, Akihiro, Ichiki, Yoshinobu, Sato, Naoko, Hisaoka, Masanori, Tanaka, Fumihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845085/
https://www.ncbi.nlm.nih.gov/pubmed/29524063
http://dx.doi.org/10.1186/s40792-018-0430-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845085/
https://www.ncbi.nlm.nih.gov/pubmed/29524063
http://dx.doi.org/10.1186/s40792-018-0430-7

Ejemplares similares